Medicago Inc. (TSX VENTURE:MDG) announced it has been awarded a non-refundable contribution of up to $279,700 from Canada’s National Research Council Industrial Research Assistance Program (”NRC-IRAP”) to support the development of the Company’s seasonal influenza Virus-Like Particles (VLP) vaccine program. Medicago is developing a seasonal vaccine based on its proprietary VLP manufacturing technology, which has the potential to offer speed and cost advantages over competitive technologies.

More: continued here

This entry was posted on Tuesday, July 8th, 2008 at 11:07 pm and is filed under Flu / SARS. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.